Role of circulating tumor DNA (ctDNA) from liquid biopsy in early-stage NSCLC resected lung tumor investigation (LIBERTI)

The detection of ctDNA after cancer surgery with curative intent may indicate the presence of minimal residual disease and a higher risk for relapse. The Addario Lung Cancer Medical Institute (ALCMI) has launched a multicenter study to evaluate the role of ctDNA in patients with completely resected stage II to III non-small cell lung cancer (NSCLC) using a highly sensitive assay developed by Inivata. This molecular residual disease (MRD) personalized assay is used to detect tumor-specific variants in plasma DNA from patients with NSCLC. The study will enroll 500 patients across three cohorts, with the initial ctDNA collection prior to neoadjuvant therapy (cohort 1), prior to surgery (cohort 2), or between the surgery and initiation of adjuvant chemotherapy (cohort 3). We will conduct an initial evaluation of ctDNA results after enrollment of 100 eligible patients. All patients will be followed for survival and recurrence for a maximum of 60 months from the date of surgery. The primary objective is to correlate the presence of ctDNA following complete surgical resection with disease-free survival. Citation Format: Daniel Morgensztern, Emma Green, Jennifer C. King, Alicia Sable-Hunt, Richard Erwin, Amy Moore, Tony Addario, Clive Morris, Ramaswamy Govindan. Role of circulating tumor DNA (ctDNA) from liquid biopsy in early-stage NSCLC resected lung tumor investigation (LIBERTI) [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr A52.